ClinicalTrials.gg

Program

JNJ-88998377

A development code.

Its studies are mostly in Lymphoma, Non-Hodgkin, led by Johnson & Johnson.

Furthest: phase 1, since Jun 17, 20241 company-led study, 1 open or runningNext primary completion: Oct 29, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson11 open or runningphase 1since Jun 17, 2024Jun 17, 2024Oct 29, 2027phase 1 · NCT06470438
  • Named in Johnson & Johnson’s own pipeline as JNJ-8377, phase 1, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 17, 2024First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT06470438 · 58 enrolled · China, Italy, Japan and more

Ahead

  1. Oct 29, 2027Primary completion: phase 1 study in Lymphoma, Non-HodgkinNCT06470438

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06470438Lymphoma, Non-Hodgkin · China, Italy, Japan and more1Active, not recruitingOct 29, 202758

How it is read

Names in the registry

  • “JNJ-88998377”, 1 entry

Codes read as this program: JNJ88998377.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.